Gland Pharma names Shyamakant Giri as new CEO
Written By : Farhat Nasim
Published On 2024-10-19 09:59 GMT | Update On 2024-10-19 09:59 GMT
New Delhi: Gland Pharma has announced a major leadership change with the appointment of Shyamakant Giri as the new Chief Executive Officer (CEO), effective January 15, 2025. The appointment, approved by the Board and recommended by the Nomination and Remuneration Committee, aims to drive the company’s next phase of growth.
Shyamakant Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in leading Indian and multinational organizations across Asia, Africa, MENA & LATAM markets. He possesses experience in creating new ventures and improving existing businesses, developing leaders, identifying opportunities for value creation, and executing with discipline. His specialties include Business Development, Operations, Strategy, Product Marketing, start-ups, and turnarounds.
Giri is currently serving as the President (India Business & Emerging Markets) of Amneal Pharmaceuticals, responsible for the commercial expansion and growth in India and Rest of the World markets. Previously, Giri was associated with Rivaara Labs as the Chief Executive Officer. Earlier, Giri was associated in various roles with Abbott India, AbbVie (India Region) and Abbott Diagnostics for almost eighteen years (2002-2020). Mr. Giri started his professional career with Wockhardt Ltd. and was associated during the period 1999-2002.
Giri has done his Master’s in Marketing Management from Jamnalal Bajaj Institute of Management Studies and also holds a Master’s degree in Science (Organic Chemistry) from Mumbai University. He completed his Executive Programme from INSEAD, Singapore and Executive Programme in Hospital Management from Indian Institute of Management, Ahmedabad.
Consequent to appointment of new CEO of the Company, Srinivas Sadu shall continue to be the Executive Chairman of the Company effective January 15, 2025. Srinivas Sadu has been a Director on the Board since April 25, 2019. Srinivas Sadu is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.